5-Methyl-2-(trifluoromethoxy)benzyl alcohol | 1261852-64-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5-Methyl-2-(trifluoromethoxy)benzyl alcohol
• 英文别名: [5-methyl-2-(trifluoromethoxy)phenyl]methanol
• CAS: 1261852-64-5
• 化学式: C₉H₉F₃O₂
• 分子量: 206.16
• InChiKey: NRDALTWSSLVMLU-UHFFFAOYSA-N

物化性质

• 沸点：
  214.0±35.0 °C(Predicted)
• 密度：
  1.289±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Sulfopyrroles
  申请人：Eberle Martin

  公开号：US20070060570A1

  公开（公告）日：2007-03-15

  The invention relates to compounds of formula (I) wherein R 1 represents aryl, aralkyl or heteroaryl, R 2 is aryl or heteroaryl and R 3 is aryl, heteroaryl or optionally substituted aminomethyl, to methods of synthesis of such compounds, to pharmaceutical compositions containing compounds of formula (I), to the use of a compounds of formula (I) for the preparation of a pharmaceutical composition for the treatment of neoplastic and autoimmune diseases, and to methods of treatment of neoplastic and autoimmune diseases using compounds of formula (I) or of pharmaceutical compositions containing same.

  本发明涉及式(I)化合物，其中R1代表芳基、芳基烷基或杂芳基，R2为芳基或杂芳基，R3为芳基、杂芳基或可选取代的氨甲基；本发明还涉及合成这类化合物的方法，含有式(I)化合物的制药组合物，使用式(I)化合物制备用于治疗肿瘤和自身免疫性疾病的制药组合物，以及使用式(I)化合物或含有其的制药组合物治疗肿瘤和自身免疫性疾病的方法。
• HERBIZID WIRKSAME 3-PHENYLISOXAZOLINDERIVATE
  申请人：Bayer CropScience AG

  公开号：EP2900645A1

  公开（公告）日：2015-08-05
• [EN] GLUCAGON ANTAGONISTS/INVERSE AGONISTS<br/>[FR] AGONISTES DE GLUCAGON/ANTAGONISTES INVERSES
  申请人：NOVO NORDISK AS

  公开号：WO2002040445A1

  公开（公告）日：2002-05-23

  A novel class of compounds of the general formula (I): wherein B is (1), (2), (3) or (4), Z is arylene or a divalent radical derived from a 5 or 6 membered heteroaromaic ring containing 1 or 2 heteroatoms selected from nitrogen, oxygen and sulfur, E is (a), (b), (c), (d), (e), (f), (g) or (h), which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.